Innova Captab Q4 FY25 earnings call transcript filed
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Innova Captab filed Q4 FY25 earnings call transcript. FY25 revenue grew 15% to INR 1,243.7 cr; PAT up 36% to INR 128.3 cr with margins expanding 160 bps to 10.3%. Q4 revenue rose 20% to INR 314.7 cr. New Jammu plant contributed INR 36 cr in Q4. Management guides Jammu at INR 400 cr in FY26 (includes INR 30-35 cr GST benefit) and targets 25% revenue CAGR over 3 years to INR 2,500 cr. Margins seen improving with operating leverage.
Strong FY25 results with margin expansion. Jammu plant ramp-up and INR 2,500 cr 3-year revenue target signal strong growth visibility for shareholders.